Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates. The adjustment reflects weaker demand for its Covid-19 and RSV vaccines, with the company projecting that most of the revenue will materialize in the second half of the year.In response, MRNA was last seen 24% lower to trade at $32.11, at its lowest level since April 2020 -- before its pandemic-era surge -- and heading for its worst-ever single-day s ...